silviu constantin badoiu

Dr. silviu constantin badoiu

UMF Carol Davila Bucharest
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MDMiricescu Daniela
Miricescu Daniela
ARALEXANDRA RIPSZKY
ALEXANDRA RIPSZKY
Iulia-Ioana Stanescu-SpinuIulia-Ioana Stanescu-Spinu
Iulia-Ioana Stanescu-Spinu
silviu constantin badoiusilviu constantin badoiu
silviu constantin badoiu
SCSTEFANI CONSTANTIN
STEFANI CONSTANTIN
Maria GreabuMaria Greabu
Maria Greabu
Breast cancer is a serious health problem worldwide, representing the second cause of death through malignancies among women in developed countries. Population, endogenous and exogenous hormones, and physiological, genetic and breast-related factors are involved in breast cancer pathogenesis. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) is a signaling pathway involved in cell proliferation, survival, invasion, migration, apoptosis, glucose metabolism and DNA repair. In breast tumors, PIK3CA somatic mutations have been reported, located in exon 9 and exon 20. Up to 40% of PIK3CA mutations are estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) -negative in primary and metastatic breast cancer. HER2 is overexpressed in 20–30% of breast cancers. HER1, HER2, HER3 and HER4 are membrane receptor tyrosine kinases involved in HER signaling to which various ligands can be attached, leading to PI3K/AKT activation. Currently, clinical studies evaluate inhibitors of the PI3K/AKT/mTOR axis. The main purpose of this review is to present general aspects of breast cancer, the components of the AKT signaling pathway, the factors that activate this protein kinase B, PI3K/AKT-breast cancer mutations, PI3K/AKT/mTOR-inhibitors, and the relationship between everolimus, temsirolimus and endocrine therapy.

Verified
Journal Article
Open access
PDF file
silviu constantin badoiusilviu constantin badoiu
silviu constantin badoiu
Maria GreabuMaria Greabu
Maria Greabu
MDMiricescu Daniela
Miricescu Daniela
Iulia-Ioana Stanescu-SpinuIulia-Ioana Stanescu-Spinu
Iulia-Ioana Stanescu-Spinu
RIRadu Ilinca
Radu Ilinca
Viorel JingaViorel Jinga
Viorel Jinga
Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent type of renal cancer in adult patients. It accounts for 3% of all cancer cases and is in 7th place among the most frequent histological types of cancer. Clear cell renal cell carcinoma (ccRCC), accounts for 75% of RCCs and has the most kidney cancer-related deaths. One-third of the patients with ccRCC develop metastases. Renal cancer presents cellular alterations in sugars, lipids, amino acids, and nucleic acid metabolism. RCC is characterized by several metabolic dysregulations including oxygen sensing (VHL/HIF pathway), glucose transporters (GLUT 1 and GLUT 4) energy sensing, and energy nutrient sensing cascade. Metabolic reprogramming represents an important characteristic of the cancer cells to survive in nutrient and oxygen-deprived environments, to proliferate and metastasize in different body sites. The phosphoinositide 3-kinase-AKT-mammalian target of the rapamycin (PI3K/AKT/mTOR) signaling pathway is usually dysregulated in various cancer types including renal cancer. This molecular pathway is frequently correlated with tumor growth and survival. The main aim of this review is to present renal cancer types, dysregulation of PI3K/AKT/mTOR signaling pathway members, crosstalk with VHL/HIF axis, and carbohydrates, lipids, and amino acid alterations.

Verified
Journal Article
Open access
PDF file
MDMiricescu Daniela
Miricescu Daniela
silviu constantin badoiusilviu constantin badoiu
silviu constantin badoiu
Iulia-Ioana Stanescu-SpinuIulia-Ioana Stanescu-Spinu
Iulia-Ioana Stanescu-Spinu
ARALEXANDRA RIPSZKY
ALEXANDRA RIPSZKY
SCSTEFANI CONSTANTIN
STEFANI CONSTANTIN
Maria GreabuMaria Greabu
Maria Greabu
Burns can be caused by various factors and have an increased risk of infection that can seriously delay the wound healing process. Chronic wounds caused by burns represent a major health problem. Wound healing is a complex process, orchestrated by cytokines, growth factors, prostaglandins, free radicals, clotting factors, and nitric oxide. Growth factors released during this process are involved in cell growth, proliferation, migration, and differentiation. Reactive oxygen species are released in acute and chronic burn injuries and play key roles in healing and regeneration. The main aim of this review is to present the roles of growth factors, reactive oxygen species, and metformin in the healing process of burn injuries.

Verified
Journal Article
Open access
PDF file
silviu constantin badoiusilviu constantin badoiu
silviu constantin badoiu
MDMiricescu Daniela
Miricescu Daniela
Iulia-Ioana Stanescu-SpinuIulia-Ioana Stanescu-Spinu
Iulia-Ioana Stanescu-Spinu
ARALEXANDRA RIPSZKY
ALEXANDRA RIPSZKY
SBSilvia Elena Bădoiu
Silvia Elena Bădoiu
Maria GreabuMaria Greabu
Maria Greabu
Severe burns represent an important challenge for patients and medical teams. They lead to profound metabolic alterations, trigger a systemic inflammatory response, crush the immune defense, impair the function of the heart, lungs, kidneys, liver, etc. The metabolism is shifted towards a hypermetabolic state, and this situation might persist for years after the burn, having deleterious consequences for the patient’s health. Severely burned patients lack energy substrates and react in order to produce and maintain augmented levels of glucose, which is the fuel “ready to use” by cells. In this paper, we discuss biological substances that induce a hyperglycemic response, concur to insulin resistance, and determine cell disturbance after a severe burn. We also focus on the most effective agents that provide pharmacological modulations of the changes in glucose metabolism.

Verified
Journal Article
Open access
PDF file
ATAnca Tigora
Anca Tigora
RPRadu Petru
Radu Petru
NGNicolae Dragos Garofil
Nicolae Dragos Garofil
MBMircea Nicolae Brătucu
Mircea Nicolae Brătucu
MZMihai Zurzu
Mihai Zurzu
SRSandu Ramboiu
Sandu Ramboiu
Inguinal hernia repair is one of the most commonly performed surgical procedures worldwide, with over 20 million cases annually. The evolution of hernia surgery has transitioned from tension-based techniques to tension-free approaches, significantly reducing recurrence rates. This review explores the history, advancements, and current trends in minimally invasive inguinal hernia repair, focusing on laparoscopic techniques such as transabdominal preperitoneal (TAPP), totally extraperitoneal (TEP), single-incision laparoscopic surgery (SILS), and robotic-assisted repair. The importance of prosthetic meshes is emphasized, detailing their mechanical properties, pore size, weight classifications, and biocompatibility. Additionally, various mesh fixation methods—including tacks, sutures, and glues—are analyzed, with a discussion on their impact on postoperative complications such as chronic pain, adhesions, and infection risk. The debate between TAPP and TEP techniques is examined, highlighting the ongoing quest to determine the most effective approach. Emerging advancements, including drug-loaded meshes and dual-layered prosthetics, aim to improve integration and reduce complications. Despite significant progress, no universally superior technique or mesh exists, underscoring the need for individualized surgical approaches. Future research should focus on optimizing materials, refining fixation strategies, and enhancing patient outcomes in minimally invasive hernia repair.

Verified
Journal Article
Open access
PDF file
Maria GreabuMaria Greabu
Maria Greabu
silviu constantin badoiusilviu constantin badoiu
silviu constantin badoiu
Iulia-Ioana Stanescu-SpinuIulia-Ioana Stanescu-Spinu
Iulia-Ioana Stanescu-Spinu
MDMiricescu Daniela
Miricescu Daniela
ARALEXANDRA RIPSZKY
ALEXANDRA RIPSZKY
Viorel JingaViorel Jinga
Viorel Jinga
It has become widely accepted that insulin resistance and glucose hypermetabolism can be linked to acute pathologies, such as burn injury, severe trauma, or sepsis. Severe burns can determine a significant increase in catabolism, having an important effect on glucose metabolism and on muscle protein metabolism. It is imperative to acknowledge that these alterations can lead to increased mortality through organ failure, even when the patients survive the initial trauma caused by the burn. By limiting the peripheral use of glucose with consequent hyperglycemia, insulin resistance determines compensatory increased levels of insulin in plasma. However, the significant alterations in cellular metabolism lead to a lack of response to insulin’s anabolic functions, as well as to a decrease in its cytoprotective role. In the end, via pathological insulin signaling associated with increased liver gluconeogenesis, elevated levels of glucose are detected in the blood. Several cellular mechanisms have been incriminated in the development of insulin resistance in burns. In this context, the main aim of this review article is to summarize some of the drugs that might interfere with insulin resistance in burns, taking into consideration that such an approach can significantly improve the prognosis of the burned patient.